Jean-Christophe Tellier, UCB CEO (Jasper Jacobs/Belga/Sipa USA/Sipa via AP Images)
UCB enters gene therapy space, inking license agreement for epilepsy and neurodegeneration research
UCB may not have any gene therapy candidates on the market or publicly in its pipeline, but that hasn’t stopped the pharma from inking a multi-year license agreement with ClearPoint Neuro to work on drug delivery platforms for UCB’s gene therapy portfolio, according to the companies.
As part of the agreement, UCB will use ClearPoint Neuro’s tech and services to develop and commercialize UCB’s gene therapy products and ClearPoint will receive success-based milestone payments. More financial details of the agreement weren’t described.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters